Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BHVN vs AGIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BHVN Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–6 Matrix Metrics)

BHVN Overall Winner 6-Pillar Tally: BHVN 3 – 2 AGIO (1 Tie) Matrix Metrics: BHVN 4 – 6 AGIO

As of Nov 16, 2026, Biohaven Ltd. (BHVN) is the stronger overall head-to-head candidate over Agios Pharmaceuticals, Inc. (AGIO) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). BHVN carries a Unified Composite Score of 42.1/100 (HOLD) at $13.90 (N/M Forward P/E, 0.0% operating margin), whereas AGIO carries 55.9/100 (HOLD) at $30.42 (2.5x Forward P/E, -297.7% operating margin).

  • Composite vs. Pillar Nuance: While AGIO currently prints a higher short-term Unified Composite Score (55.9/100 HOLD vs. BHVN 42.1/100 HOLD), BHVN captures the overall institutional head-to-head verdict (4–6 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -297.7% operating margin) and revenue trajectory (+0.0% vs. +330.0% YoY).
  • Technical & Structure Timing Caution: BHVN is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.4); meanwhile AGIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BHVN vs AGIO
BHVN NYSE Head-to-Head Winner
Biohaven Ltd.
Pharmaceutical Preparations
$13.90
+0.62% 1D
Market Cap $2.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.41β · 111% Vol
Unified Composite Score
42.1 / 100 HOLD
Tech 15.0 Fund 42.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -0.9%) with fading momentum, RSI 48
RSI-14: 48.4 · SMA20: $14.55 · SMA50: $13.48
AGIO NASDAQ
Agios Pharmaceuticals, Inc.
Pharmaceutical Preparations
$30.42
-3.7% 1D
Market Cap $1.9B
TTM Revenue $141M
Forward P/E 2.5x
Beta / 30D Vol 1.12β · 85% Vol
Unified Composite Score
55.9 / 100 HOLD
Tech 68.0 Fund 63.0 Flow 50.0 Mom 53.3
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -0.2%), weak momentum, RSI 43
RSI-14: 42.8 · SMA20: $33.44 · SMA50: $33.03

6-Pillar Scorecard Institutional Category Breakdown (BHVN 3 – 2 AGIO)

Columns: Metric · BHVN · AGIO
1. Valuation Multiples AGIO
Forward P/E N/M 2.5x
Trailing P/E N/M 2.5x
PEG Ratio N/M N/M
EV / Revenue N/M 13.5x
2. Growth & Scale AGIO
Revenue Growth (YoY) +0.0% +330.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $141M
Market Cap $2.1B $1.9B
3. Profitability & Quality BHVN
Gross Margin N/A N/A
Operating Margin 0.0% -297.7%
Net Profit Margin 0.0% -264.8%
Return on Equity (ROE) -799.5% -33.0%
4. Balance Sheet & Cash Flow BHVN
Cash Generation (TTM) -$473M -$414M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $205M Net Debt $16.38 Book/Sh · -33.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BHVN
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 91.5% (18th %ile) 65.7% (16th %ile)
Put/Call OI Skew 0.31x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Distribution NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BHVN (4) vs AGIO (6)
Institutional Metric BHVN AGIO Criterion Row Edge
Market Capitalization
Scale
$2.1B $1.9B Larger Scale BHVN
Trailing P/E Ratio
Valuation
N/M 2.5x Lower Multiple AGIO
Forward P/E Ratio
Valuation
N/M 2.5x Lower Multiple AGIO
Revenue Growth (YoY)
Growth
+0.0% +330.0% Higher Growth AGIO
Operating Margin (TTM)
Profitability
0.0% -297.7% Higher Margin BHVN
Net Profit Margin
Profitability
0.0% -264.8% Higher Margin BHVN
Return on Equity (ROE)
Capital Efficiency
-799.5% -33.0% Higher ROE AGIO
52-Week Range Position
Momentum
59% ($8–$18) 34% ($22–$46) Stronger Trend BHVN
Beta / 30D Volatility
Risk Regime
1.41β · 111% Vol 1.12β · 85% Vol Lower Realized Risk AGIO
Unified Institutional Score
Composite Signal
42.1 / 100 (HOLD) 55.9 / 100 (HOLD) Higher Composite AGIO
Trailing 12M Revenue (USD)
Operating Scale
N/A $141M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 13.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$473M ($205M Net Debt) -$414M EBITDA ($16.38 Book/Sh · -33.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BHVN +31.86 pp
BHVN: +28.99% · AGIO: -2.87%
3M Horizon BHVN +14.04 pp
BHVN: +2.47% · AGIO: -11.57%
6M Horizon BHVN +55.95 pp
BHVN: +63.78% · AGIO: +7.83%
1Y Horizon BHVN +100.58 pp
BHVN: +72.09% · AGIO: -28.49%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BHVN vs AGIO. Trailing 12-month operating profitability (BHVN 0.0% vs AGIO -297.7%) and valuation multiples (BHVN N/M vs AGIO 2.5x Forward P/E) are benchmarked directly in Pillar 4 below.

BHVN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-799.5% · N/M
AGIO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$141M
Gross MarginN/A
Op. Margin-297.7%
ROE / Fwd P/E-33.0% · 2.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BHVN CONSOLIDATION
91d in phase · OBV NEUTRAL
Current IV 91.5%
IV Percentile 18th %ile
Put/Call OI Skew 0.31x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact BHVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AGIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 65.7%
IV Percentile 16th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AGIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BHVN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AGIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.9B market capitalization and -297.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BHVN vs AGIO Key Questions & Quantitative Answers

As of Nov 16, 2026, Biohaven Ltd. (BHVN) is the stronger overall head-to-head candidate over Agios Pharmaceuticals, Inc. (AGIO) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). BHVN carries a Unified Composite Score of 42.1/100 (HOLD) at $13.90 (N/M Forward P/E, 0.0% operating margin), whereas AGIO carries 55.9/100 (HOLD) at $30.42 (2.5x Forward P/E, -297.7% operating margin). Composite vs. Pillar Nuance: While AGIO currently prints a higher short-term Unified Composite Score (55.9/100 HOLD vs. BHVN 42.1/100 HOLD), BHVN captures the overall institutional head-to-head verdict (4–6 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -297.7% operating margin) and revenue trajectory (+0.0% vs. +330.0% YoY). Technical & Structure Timing Caution: BHVN is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.4); meanwhile AGIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AGIO leads the Growth & Scale pillar: BHVN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with AGIO at +330.0% YoY revenue growth and +0.0% YoY earnings growth on $141M TTM revenue (N/A gross margin, -297.7% operating margin). On trailing 12-month operating scale, BHVN generates N/A in USD-normalized revenue versus $141M for AGIO. In operating R&D and SG&A reinvestment, BHVN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AGIO.

AGIO screens cheaper on headline valuation multiples. BHVN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas AGIO trades at 2.5x Forward P/E, 2.5x Trailing P/E, N/M PEG, and 13.5x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BHVN (-799.5% ROE) versus AGIO (-33.0% ROE) capital efficiency.

In options market volatility and institutional positioning, BHVN carries 91.5% implied volatility (18th %ile, Compressed (<25th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.41β · 111% Vol realized risk). By comparison, AGIO carries 65.7% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.12β · 85% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.